Claims
- 1. A compound of the formula:
- 2. The compound of claim 1 wherein X′ is OCx where Cx is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl.
- 3. The compound of claim 2 wherein Cx is phenyl or substituted phenyl.
- 4. The compound of claim 1 wherein j is 0.
- 5. The compound of claim 1 wherein q is 0 or 1.
- 6. The compound of claim 1 wherein Z′ is hydrogen or methyl and Z″ is hydrogen.
- 7. The compound of claim 1 has an (E) geometry.
- 8. The compound of claim 1 wherein m and/or n are 0.
- 9. The compound of claim 1 wherein m is 1 and n is 0, and E is hydrogen and EI is methyl.
- 10. The compound of claim 1 wherein m is 1 and n is 1, and E, EI and EII each are hydrogen and EIII is methyl.
- 11. The compound of claim 1 wherein the sum of m plus n is 1 or 2.
- 12. The compound of claim 1 wherein Q is
- 13. The compound of claim 1, (S)-(E)-3(2-pyrrolidin-2-ylvinyl) pyridine.
- 14. The compound of claim 1, (E)-(S)-3-(4-hydroxyphenoxy)-5-(pyrrolidin-2-ylvinyl)pyridine.
- 15. The compound of claim 1, (E,S)-3-cyclopentyloxy-5-(pyrrolidin-2-ylvinyl)pyridine.
- 16. A compound of the formula:
- 17. The compound of claim 16 wherein X′ is nitrogen bonded to oxygen.
- 18. The compound of claim 16 wherein X″ is nitrogen.
- 19. The compound of claim 16 wherein 1 or 2 of X, X′ and X″ are nitrogen or nitrogen bonded to oxygen.
- 20. The compound of claim 16 wherein one of X, X′ and X″ is nitrogen bonded to oxygen.
- 21. The compound of claim 16 wherein both X′ and X″ are nitrogen.
- 22. The compound of claim 16 wherein X′ is OCy where Cy is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic hetero-cyclylalkyl.
- 23. The compound of claim 16 wherein Q is
- 24. The compound of claim 16 selected from the group consisting of (S)-5-(2-pyrrolidin-2-ylethynyl)pyrimidine, (R)-5-(2-pyrrolidin-2-ylethynyl)pyrimidine, (S)-5-(2-pyrrolidin-2-ylethynyl)pyridine, (R)-5-(2-pyrrolidin-2-ylethynyl)pyridine, (S)-3-isopropoxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-phenyl-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(phenoxyphenyl)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-methoxyphenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-hydroxyphenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-cyclopentyloxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-cyclohexyloxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-(pyrrolidine-1-sulfonyl)phenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(3-pyridyloxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(pyrrolidin-2-ylethynyl-5-(tetrahydropyran-4-yloxy)pyridine and (S)-3-(3,5-dihydroxy)phenoxy-5-(pyrrolidin-2-ylethynyl)pyridine.
- 25. A pharmaceutical composition incorporating a compound of:
- 26. The pharmaceutical composition of claim 25 wherein X′ is OCx where Cx is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl.
- 27. The pharmaceutical composition of claim 26 wherein Cx is phenyl or substituted phenyl.
- 28. The pharmaceutical composition of claim 25 wherein j is 0.
- 29. The pharmaceutical composition of claim 25 wherein q is 0 or 1.
- 30. The pharmaceutical composition of claim 25 wherein Z′ is hydrogen or methyl and Z″ is hydrogen.
- 31. The pharmaceutical composition of claim 25 has an (E) geometry.
- 32. The pharmaceutical composition of claim 25 wherein all of E, EI, EII and EIII individually are hydrogen.
- 33. The pharmaceutical compositionof claim 25 wherein m and/or n are 0.
- 34. The pharmaceutical composition of claim 25 wherein m is 1 and n is 0, and E is hydrogen and EI is methyl.
- 35. The pharmaceutical composition of claim 25 wherein m is 1 and n is 1, and E, EI and EII each are hydrogen and EIII is methyl.
- 36. The pharmaceutical composition of claim 25 wherein the sum of m plus n is 1 or2.
- 37. The pharmaceutical composition of claim 25 wherein Q is
- 38. The pharmaceutical composition of claim 25 wherein the compound is, (S)-(E)-3(2-pyrrolidin-2-ylvinyl) pyridine.
- 39. The pharmaceutical composition of claim 25 wherein the compound is, (E)-(S)-3-(4-hydroxyphenoxy)-5-(pyrrolidin-2-ylvinyl)pyridine.
- 40. The pharmaceutical composition of claim 25 wherein the compound is, (E,S)-3-cyclopentyloxy-5-(pyrrolidin-2-ylvinyl)pyridine.
- 41. A pharmaceutical composition incorporating a compound of the formula:
- 42. The pharmaceutical composition of claim 41 wherein X″ is nitrogen bonded to oxygen.
- 43. The pharmaceutical composition of claim 41 wherein X″ is nitrogen.
- 44. The pharmaceutical composition of claim 41 wherein 1 or 2 of X, X′ and X″ are nitrogen or nitrogen bonded to oxygen.
- 45. The pharmaceutical composition of claim 41 wherein one of X, X′ and X″ is nitrogen bonded to oxygen.
- 46. The pharmaceutical composition of claim 41 wherein X″ is nitrogen.
- 47. The pharmaceutical composition of claim 41 wherein both X′ and X″ are nitrogen.
- 48. The pharmaceutical composition of claim 41 wherein X′ is OCy where Cy is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic hetero-cyclylalkyl.
- 49. The pharmaceutical composition of claim 41 wherein Q is
- 50. The pharmaceutical composition of claim 41 wherein the compound is selected from the group consisting of (S)-5-(2-pyrrolidin-2-ylethynyl)pyrimidine, (R)-5-(2-pyrrolidin-2-ylethynyl)pyrimidine, (S)-5-(2-pyrrolidin-2-ylethynyl)pyridine, (R)-5-(2-pyrrolidin-2-ylethynyl)pyridine, (S)-3-isopropoxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-phenyl-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(phenoxyphenyl)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-methoxyphenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-hydroxyphenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-cyclopentyloxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-cyclohexyloxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-(pyrrolidine-1-sulfonyl)phenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(3-pyridyloxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(pyrrolidin-2-ylethynyl)-5-(tetrahydropyran-4-yloxy)pyridine and (S)-3-(3,5-dihydroxy)phenoxy-5-(pyrrolidin-2-ylethynyl)pyridine.
- 51. A method for treating a central nervous system disorder, said method comprising administering an effective amount of a compound having the formula:
- 52. The method of claim 51 wherein X′ is OCx where Cx is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl.
- 53. The method of claim 51 wherein Cx is phenyl or substituted phenyl.
- 54. The method of claim 51 wherein j is 0.
- 55. The method of claim 51 wherein q is 0 or 1.
- 56. The method of claim 51 wherein Z′ is hydrogen or methyl and Z″ is hydrogen.
- 57. The method of claim 51 in has an (E) geometry.
- 58. The method of claim 51 wherein m and/or n are 0.
- 59. The method of claim 51 wherein m is 1 and n is 0, and E is hydrogen and EI is methyl.
- 60. The method of claim 51 wherein m is 1 and n is 1, and E, EI and EII each are hydrogen and EIII is methyl.
- 61. The method of claim 51 wherein the sum of m plus n is 1 or 2.
- 62. The method of claim 51 wherein Q is
- 63. The method of claim 51 wherein the compound is, (S)-(E)-3(2-pyrrolidin-2-ylvinyl)pyridine.
- 64. The method of claim 51 wherein the compound is, (E)-(S)-3-(4-hydroxyphenoxy)-5-(pyrrolidin-2-ylvinyl)pyridine.
- 65. The method of claim 51 wherein the compound is, (E,S)-3-cyclopentyloxy-5-(pyrrolidin-2-ylvinyl)pyridine.
- 66. A method for treating a central nervous system disorder, said method comprising of the administration of an effective amount of a compound having the formula:
- 67. The method of claim 66 wherein X″ is nitrogen bonded to oxygen.
- 68. The method of claim 66 wherein X″ is nitrogen.
- 69. The method of claim 66 wherein 1 or 2 of X, X′ and X″ are nitrogen or nitrogen bonded to oxygen.
- 70. The method of claim 66 wherein one of X, X′ and X″ is nitrogen bonded to oxygen.
- 71. The method of claim 66 wherein X″ is nitrogen.
- 72. The method of claim 66 wherein both X′ and X″ are nitrogen.
- 73. The method of claim 66 wherein X′ is OCy where Cy is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic hetero-cyclylalkyl.
- 74. The method of claim 66 wherein Q is
- 75. The method of claim 66 whereing the compound is selected from the group consisting of (S)-5-(2-pyrrolidin-2-ylethynyl)pyrimidine, (R)-5-(2-pyrrolidin-2-ylethynyl)pyrimidine, (S)-5-(2-pyrrolidin-2-ylethynyl)pyridine, (R)-5-(2-pyrrolidin-2-ylethynyl)pyridine, (S)-3-isopropoxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-phenyl-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(phenoxyphenyl)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-methoxyphenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-hydroxyphenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-cyclopentyloxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-cyclohexyloxy-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(4-(pyrrolidine-1-sulfonyl)phenoxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(3-pyridyloxy)-5-(pyrrolidin-2-ylethynyl)pyridine, (S)-3-(pyrrolidin-2-ylethynyl)-5-(tetrahydropyran-4-yloxy)pyridine and (S)-3-(3,5-dihydroxy)phenoxy-5-(pyrrolidin-2-ylethynyl)pyridine.
RELATED APPLICATION
[0001] This application claims priority from U.S. Provisional Application 09/431,700, filed Nov. 1, 1999, the disclosure of which is incorporated by reference herein in its entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09431700 |
Nov 1999 |
US |
Child |
09845526 |
Apr 2001 |
US |